Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Is HER2-low a distinct subtype of breast cancer?

Paolo Tarantino • 12 Sep 2022
ESMO 2022
Breast Cancer Antibodies Trastuzumab deruxtecan

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on HER2-low breast cancer. HER2-low is not a distinct subtype of breast cancer but has been shown to be an important biomarker for novel antibody-drug conjugates such as trastuzumab deruxtecan. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Tarantino

2:24
Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
Paolo Tarantino • 5 Jun 2023
1:29
Takeaways on the management of early-stage TNBC
Paolo Tarantino • 5 Jun 2023
2:23
Prognosis and trends in chemotherapy use for patients with stage IA TNBC
Paolo Tarantino • 5 Jun 2023
4:08
SABCS 2022 highlights
Paolo Tarantino • 8 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals